Regeneration of injured axons following injury depends on a delicate balance between growth-promoting and growth-inhibiting factors. Overexpression of neurotrophin genes seems a promising strategy to promote regeneration. Trophic genes can be overexpressed at the site of injury at the axonal stumps, or at the perikaryal level of the injured neuron. Transduction of the neural cells can be achieved by applying adenoviral vectors, either directly in vivo or-in the case of neurotransplantation-as an ex vivo approach. In both cases it would create a more permissive environment for axonal growth and therefore in functional regenera tion. In this article, the feasibility of the use of adenoviral vectors in several neuroregeneration models-in particularly in spinal cord lesion models and the biological clock transplantation model-is illustrated. The results show that the adenoviral vectors can be a powerful tool to study the effects of overexpression of genes in an in vivo paradigm of nerve regeneration or nerve outgrowth. The potential use of adenoviral vectors and ex vivo transduced neurotransplants is discussed.
]. This dichot omy of the regenerative capacity is due to several mo lecular and cellular differences between the PNS and CNS. Most notable is that the neuroglia cells of a pe ripheral nerve, the Schwann cells, express an array of growth-promoting proteins and lack the inhibitory com ponents expressed by oligodendrocytes, astrocytes, and fibroblasts in the CNS (6, 7, 22, 43, 46, 47) . Brain repair by transplantation of fetal CNS neurons to replace degener ating or lost central neurons is similarly hampered by limited neurite outgrowth from grafted neurons towards the denervated target cells in the adult host CNS. In ad dition, neurografting is hampered by problems related to the limited survival of grafted fetal neurons (5, 39, 52) .
Several mechanisms appear to underlie the restricted neuritic outgrowth of injured adult CNS neurons or of transplanted fetal neurons in the CNS of the host. First, the upregulation of neuronal growth-associated proteins (e.g., B-50/GAP-43), cell adhesion molecules (e.g., LI), and transcription factors (e.g., c-jun) is needed to regen erate an axon into a growth-permissive environment.
Following axonal injury, however, many populations of CNS neurons either do not, or only transiently, upregulate B-507GAP-43, nor do they extend axons into growth-permissive peripheral nerve implants (12, 32, 50, 53, 55) . Second, although CNS neurons exhibit sensitiv ity to a variety of growth factors, this relatively low ex pression in injured adult brain may critically contribute to the failure of axonal regeneration following injury (21, 32, 57) or neurite formation following neurografting.
Finally, the adult host CNS environment contains neu rite growth-inhibiting factors, some of which are in duced in response to the damage (7, 42, 47) .
Overexpression of neurotrophic factors is a strategy used to enhance regeneration of neurites of injured adult neurons or of fetal neurons transplanted in or near an adult CNS lesion site. In view of the fact that it is diffi cult to apply sufficient amounts of these proteins locally at brain lesion sites, using viral vectors to introduce genes for neurotrophic factors directly in cells of the injured nervous system, or ex vivo in neural transplants, are important and relatively new options (16, 28) . Gene transfer to postmitotic cells has been achieved with her pes viral (HSV), adenovirus-associated viral (AAV), lentiviral and adenoviral vectors [for review see (28) ]. These vectors are not dependent on host cell replication and they allow expression of a foreign gene in a wide range of postmitotic or slowly dividing cells (1, 3, 15, 26) . All these viral vector systems have also been used to introduce foreign genes into the cells of the nervous sys tem, either by direct injection of the vector or by using an ex vivo strategy [for review see (28, 54) ]. Adenoviral vectors transduce almost every cell type in the nervous system, including Schwann cells (1, 17, 48) , and thus can be used in a number of different strategies aiming to promote axonal regeneration and neuronal survival.
In the present article, the possibilities of the applica tion of adenoviral vectors are illustrated in specific ro dent models for regeneration or repair. Application of adenoviral vectors at the level of the perikaryon of an axotomized neuron, or at its injury site, is illustrated by direct in vivo vector injection. Furthermore, ex vivo transduction prior to implantation of fetal suprachiasmatic nucleus (SCN) tissue is shown as a neural grafting repair model. Finally, the use of ex vivo adenoviral vec tor-mediated transduced peripheral nerve tissue bridges implanted in a spinal cord hemitransection is described. The rationale for all these studies is that overexpression of neurotrophic factors would support the survival and regeneration of injured neurons, or would stimulate neuritic outgrowth of grafted neurons.
ADENOVIRAL VECTORS
The currently used adenoviral vectors are based on adenovirus type 5 (Ad5), which causes mild respiratory inflammation in humans. The adenovirus genome con tains 36 kb of DNA and is flanked by two inverted ter minal repeats (ITRs). The adenoviral genes can be di vided in two main categories: early genes (E-genes) and late genes (L-genes). El is the first gene to be expressed after infection of a cell and serves as an activator for viral gene expression and replication of the virus. The first generation recombinant adenoviral vectors are all based on the substitution of the El gene with a transgene expression cassette, deletion of which renders a replica tion-defective viral vector that is capable of expressing a transgene in infected cells (1, 3, 14, 26) . Following in fection of a cell, the adenoviral vector genome does not integrate into the host genome but remains episomal. Therefore, cell division results in the gradual loss of the adenoviral vector genome (37) .
The generation of a first-generation adenoviral vector is illustrated in Figure 1 . Briefly, an adenoviral targeting plasmid is constructed containing the left ITR, a suitable expression cassette [often using the human cytomegalo virus (CMV) promoter], followed by a fragment of the Ad5 genome (map units 9.2-15.5). Addl309 DNA is di gested with Clal and Xbal to remove the left ITR and both DNAs are cotransfected into a helper cell harboring the El gene (911 or 293 cell). Following homologous recombination, a recombinant adenoviral vector is formed that can be packaged, plaque-purified, and propagated in helper cells (1, 3, 15, 18, 26) . In the present study we describe results obtained with adenoviral vectors for the reporter gene LacZ (Ad-LacZ) and for neurotrophin-3 (Ad-NT-3).
DIRECT APPLICATION OF ADENOVIRAL VECTORS TO NEURAL TISSUE
Adenoviral vectors have been shown to transduce many neural and glial cells following injection in the brain. The facial nucleus of the rat contains motor neu rons with axonal projections in the facial nerve. Trans duction of facial motor neurons allows studying the ef fect of expressed gene products on the regeneration of these neurons following injury to the facial nerve. Fol lowing injection of 10 7 plaque-forming units (pfu) Ad-LacZ into the facial nucleus, transduction of the nucleus is observed using histochemistry to label the gene prod uct P-galactosidase ( Fig. 2 ). Neuronal transgene expres sion is high during the first week, decreases during the second week, and is nearly depleted 3 weeks postinjection of the viral vector (26, 27) . The period of loss of transduced neurons coincides with T-cell infiltration, in dicative of an immunological rejection response. Fol lowing injection of the vector into nude T-cell-deficient rats, transgene expression in astroglial cells can still be observed at 3 weeks postinjection, while transduced mo tor neurons degenerate due to neurotoxicity to the viral vector (8, 26) . The transgene expression period can also be prolonged when the animals are treated with an im munosuppressant, dexamethasone, for the first 3 days postsurgery (27) . Although most transduced neurons do not survive, a population of glial cells continues to ex press the transgene. Similar injections of recombinant adenoviral vectors also efficiently transduce neurons and glial cells in the spinal cord (34) (35) (36) 59) . Robust trans gene expression is observed between 4 and 40 days after injection of 10 7 pfu Ad-LacZ ( Fig. 2 ).
As an alternative to the above applied first-generation recombinant adenoviral vectors, recently defective ade noviral vectors deleted of all viral genes have been gen erated (24, 33, 41) , and designated as "minimal" or "gut less" adenoviral vectors. Also, vectors less toxic to neurons have been developed to prolong transgene ex pression and reduce the immune response and neurotox icity to viral genes, including recombinant AAV or len tiviral vectors [for review see (28) ]. So far, however, 
EX VIVO GENE TRANSFER IN FETAL BRAIN TISSUE AND ADULT PERIPHERAL NERVE IMPLANTS
As a first step to develop methods for ex vivo trans duction of fetal neural transplants, in vitro studies were performed to determine the optimal procedure for infec tion. Rat fetal embryonic day 17 (E17) SCN tissue was used, similar to that prepared for neurografting in the SCN lesion/transplantation model to study this biologi cal clock system (4). These minced tissue blocks were cultured as neural explants, and were subjected to im mersion infection with Ad-LacZ (5,51,52). Optimal con ditions for transgene expression were obtained by over night immersion in approximately 2 x 10 8 pfu/ml (5, 51) . of the adenoviral vector as the in vivo inflammatory re sponse was comparable in control and Ad-LacZ-treated transplants (5, 51) . Both nontreated control and Ad-LacZ-infected transplants showed similar survival for the SCN. Furthermore, intraimplant neuritic growth of SCN cells was not hampered by the presence of Ad-LacZ transduced cells (Fig. 4 ). In addition, TrkC recep tors have recently shown to be present on fetal SCN cells (25) . The above studies therefore suggest that ex vivo adenoviral vector-mediated gene transfer could, in principle, enhance the local production of NT-3 or other outgrowth-or survival-promoting proteins in a SCN transplant with the potential to improve functional inte gration of such grafts. Transplantation of peripheral nerves or Schwann cells derived from peripheral nerves has been employed to show that CNS neurons are capable of long distance re generation within the growth-permissive environment of such transplants. Peripheral nerve implants placed in the CNS stimulate outgrowth of several populations of CNS neurons. For instance, such implants placed in the cervi cal spinal cord or in the thalamus allow regeneration of fibers over distances of several centimeters from dam aged adult neurons in the brain stem or the substantia nigra [ (9, 12, 13, 32, 44, 58) ; for review see (2)]. Semiper meable tubes, filled with purified primary Schwann cells, implanted to bridge a totally transected spinal cord foster ingrowth of axons from sensory and motor neu rons as well as from neurons within the brain stem and raphe nucleus (23, 56, 57) . Schwann cells are also able to remyelinate these regenerating CNS axons (23) . Overexpression of neurotrophic factors (or cell adhesion mole cules) in such peripheral nerve or Schwann cell implants could enhance the growth-permissive properties of these implants for the host neurites. Implantation of Ad-LacZ transduced pieces of intercostal nerves in two lesion models (implantation into the transected sciatic nerve and the dorsally hemisected spinal cord) displayed (3galactosidase expression at 7 days postgrafting (Fig. 2C,  D) , with a decline during the second week postimplanta tion and no expression thereafter (B. Blits et al., unpub lished). The implants remained visible as peripheral nerve at the site of implantation. ED-1 staining showed that macrophages entered the site of lesion, but did not enter the implant (data not shown). The Schwann cells of the transduced intercostal nerve piece clearly retained the capacity to guide regenerative ingrowth of nerve fi bers (16) . Ex vivo gene transfer of regeneration-associ ated genes into peripheral nerve implants, subsequently applied as bridges in transected peripheral nerves or spi nal cord, could therefore be exploited in the initial stages of regeneration of axons of injured neurons.
FUTURE PERSPECTIVES
The use of viral vector-mediated gene transfer is a promising strategy to promote neuroregeneration, either by direct transduction of injured neural tissue or by ex vivo transduction of neural grafts. In the present studies using first-generation adenoviral vector encoding the marker gene LacZ, the feasibility of the approach is es tablished in several models for neuroregeneration. Thus, in principle, adenoviral vectors for neurotrophins can be applied to direct local and high-level expression of bioactive neurotrophins near injured neurons as a means of studying their effects on axonal regeneration within in vivo paradigms as well as to improve functional recov ery following neural grafting. Such vectors provide a continuous and local supply of the neurotrophin of choice near the cell bodies or axonal tips of injured neu rons to stimulate survival and neurite regrowth within the CNS. In order to assess whether the use of Ad-NT-3 would indeed result in the expression of biologically active NT-3, rat E17 dorsal root ganglia (DRG) explants have been infected by immersion with either Ad-LacZ or Ad-NT-3 (17) . The Ad-NT-3 transduction resulted in robust neurite outgrowth compared to Ad-LacZ treat ment (Fig. 5) . So, an adenoviral vector encoding a neu rotrophin produces and releases sufficient amounts of biologically active neurotrophin. Similar results have previously been obtained with HSV vectors encoding for nerve growth factor (NGF) or brain-derived neuro trophic factor (BDNF) (18, 19) .
Although first-generation adenoviral vectors appear to be toxic to many types of neurons following direct injection in the CNS (including the spinal motor neu rons), and may therefore not be suitable in all neurore generation models, the principle of viral vector-mediated expression of a neurotrophic factor (i.e., NT-3) within a neuronal target field as a means of stimulating axonal regrowth has recently been established in a dorsal root injury rat model. The axons in a transected dorsal root are usually unable to regrow through the dorsal root en try zone (DREZ) of the spinal cord. Because a subpopulation of these axons is NT-3 sensitive, introduction of the NT-3 gene in the gray matter of the spinal cord was offered as an approach to attract and regrow otherwise intractable spinal root fibers into the DREZ (40) and eventually into the spinal cord gray matter. In these ex periments, the dorsal roots of the 4th to 6th lumbar spi nal nerves were severed and reanastomosed. Injection of adenoviral vectors containing either the LacZ or NT-3 genes into the ventral horn of the lumbar spinal cord then followed 14-19 days later. This results in expres sion of transgene up to 42 days (15) . When dorsal root axons were finally transganglionically labeled 16 to 37 days after the injury, large numbers of labeled axons could be seen to have regenerated into the cord, but only in those animals injected with vector carrying the NT-3 gene. The regenerated axons were found at the injection site, mainly in the gray matter, and had penetrated as deep as lamina V (58) . These results demonstrate that gene transfer with adenoviral vectors encoding a neuro trophin is therefore capable of enhancing and directing the regeneration of dorsal root axons into and through the CNS environment. Such a local viral vector-directed expression of neurotrophins has the advantage that the growth-promoting action of the neurotrophin can be pro duced and secreted at the natural site of termination of injured neurons, following a single injection. In the dor sal root lesion model, the viral vector treatment appeared toxic to the motor neurons. Yet, other nontoxic viral vectors that have been developed for in vivo neuronal transduction, such as "gutless" adenoviral vectors, AAV vectors, or lentiviral vectors, are still to be employed in this model.
The results of long-term expression of the reporter gene LacZ in SCN grafts has shown that adenoviral vec tors can be successfully used in transplantation studies. Here, possible neuronal toxicity of the adenoviral vector plays a limited role because initial cell survival is more affected by transient ischemia due to initial absence of vascularization (5, 50) . In fact, the sustained survival of both transduced neurons and glial cells in the ex vivo infected SCN grafts for at least 7 months (51) indicates that the toxicity of the same vector, when applied as direct brain injection, must be due to effects of the vec tor particles on neural cells. The immune responses ob served following direct injection in the brain paren chyma are indeed not observed following grafting of ex vivo transduced fetal brain tissue in which the viral vec tor is packaged intracellularly (5, 37) . Ex vivo graft transduction using adenoviral vectors appears, therefore, to be a potentially valuable approach for expressing pro teins within the transplant that promote neuronal sur vival and neurite outgrowth and, eventually, functional integration of the implant within the transplantation site. Transduction of SCN transplants with adenoviral vectors would locally produce a source of neurotrophins, from which SCN cells could take advantage for both survival and neurite growth. NT-3 might be a candidate neuro trophin because fetal SCN cells express the TrkC recep tor (25) .
A possible important application of adenoviral vec tor-mediated neurotrophin expression relates to the use of neurotransplantation of fetal neurons as an approach to compensate for neural loss or neuronal degeneration in neurologic disorders such as Parkinson's or Hunting ton's disease. The low survival rate of grafted neurons and the relatively limited ingrowth of fibers from the graft into the host brain remain the major obstacles to successful neurotransplantation in these human diseases (39) . If a population of fetal neurons could be infected prior to transplantation using an adenoviral vector en coding a specific neurotrophin, a sustained supply of that neurotrophin would be available to the neurons of interest. For example, fetal ventral mesencephalic grafts currently being experimentally applied in Parkinson's patients could be constructed to generate glial cell linederived neurotrophic factor (GDNF), which would be 
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